Oridion Announces Major Medical Research and Congress Presentations



    JERUSALEM and NEEDHAM, Massachusetts, June 17 /CNW/ - Oridion Systems
Ltd. - (SWX: ORIDN) Significant findings from numerous medical research
projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2)
monitoring using Microstream(R) capnography technology, were recently
presented at medical congresses in the United States and Europe.
    During Digestive Disease Week (DDW) in San Diego, California, Dr. Vargo,
of the Cleveland Clinic, presented a blinded study that analyzed 122
randomized patients and showed that Microstream(R) capnography "significantly
reduces the proportion of patients with hypoxemia, major hypoxemia, apnea and
oxygen requirements during ERCP (Endoscopic Retrograde
Cholangiopancreatography) and EUS (Endoscopic ultrasound).
    Other studies describing the clinical value of Microstream(R) EtCO2
monitoring were presented during the European Resuscitation Council (ERC) in
Ghent, Belgium and the European Society of Anesthesiology (ESA) in Copenhagen,
Denmark. At ERC, two oral presentations were given and a Capnography Symposium
took place with three distinguished clinicians and the clinical practice
manager from London Ambulance Service. The four presentations showed the value
of capnography in pre-hospital care (trauma, intubations, and ROSC). The
Symposium was moderated by Prof. Pierre Carli, President Societe Francaise
d'Anesthesie et de Reanimation (French Society of Anesthesia and Intensive
Care).
    Two medical presentations given at European Society of Anesthesia
demonstrated the importance of capnography for non-intubated and intubated
patients. In a study on the use of continuous non-invasive arterial CO2
estimation in spontaneously breathing patients after craniotomy, Dr. Wolter
from France showed a good correlation between capnography and arterial blood
gas analysis in sedated patients under regional anesthesia.
    "These recent studies continue to confirm that patients are safer when
their caregivers use Oridion Microstream(R) capnography technology," stated
Gerry Feldman, President of Oridion Capnography. "The results of these global
research projects clearly demonstrate that capnography improves patient safety
and should be included in hospital and pre-hospital ventilatory monitoring
strategies."
    Oridion is the global leader of innovative capnography monitoring
solutions helping to improve patient safety, and its Microstream(R)
capnography technology has become the standard of care in ventilation
monitoring.

    A full list of these medical abstracts can be found on the Oridion
website:
http://www.oridion.com/global/english/clinical_solutions/overview/research.htm
l.
    Next financial reporting:
    August 18, 2008 Results Q2 / Half Year 2008
    November 10, 2008 Results Q3 / Nine Months 2008

    About Oridion

    Oridion Systems Ltd. (www.oridion.com) is a global medical device company
specializing in patient safety monitoring. The Company operates through wholly
owned subsidiaries in the United States, Europe, and Israel.

    Oridion develops proprietary medical devices and patient interfaces,
based on its patented Microstream(R) technologies, for the enhancement of
patient safety through the monitoring of the carbon dioxide (CO2) in a
patient's breath. These products provide effective, proven airway management
and are used in various clinical environments, including procedural sedation,
pain management, operating rooms, critical care units, post-anesthesia care
units, emergency medical services, transport, alternate care and other
settings where patients' ventilation may be compromised and at risk.

    Certain statements made herein that are not historical are
forward-looking. The words "estimate" "project" "intend" "expect" "believe"
and similar expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks and
uncertainties. Many factors could cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements that may be expressed or implied by such
forward-looking statements, including, among others, our ability to maintain
profits, the market demands for our Capnography products, our ability to focus
our team on the Capnography business, changes in general economic and business
conditions, inability to maintain market acceptance to the Company's products,
inability to timely develop and introduce new technologies, products and
applications, rapid changes in the market for the Company's products, loss of
market share and pressure on prices resulting from competition, introduction
of competing products by other companies, inability to manage growth and
expansion, loss of key OEM partners, factors effecting OEM partners' position
in the market, inability to attract and retain qualified personnel, inability
to protect the Company's proprietary technology.





For further information:

For further information: Alan Adler, Chairman and Chief Executive
Officer, Gerry Feldman, President, Walter Tabachnik, Chief Financial Officer,
Elena Gerberg, Investor Relations, e-mail: investor@oridion.com, phone:
+972-2-589-9159, address: Oridion Systems Ltd., P.O. Box 45025, 91450
Jerusalem, Israel

Organization Profile

ORIDION SYSTEMS LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890